The microbiota shares a diverse range of functions, e.g., metabolic functions, host immune system development, protect against pathogens, production of vitamins, digestion of food, and produce chemicals to fight off disease-causing pathogens, and thus plays an important role in maintaining human health and has tremendous impact on our body physiology, both in health and in disease conditions. [1] [2] [3] Bidirectional signaling between the gastrointestinal tract and the brain by means of the "vagus" comprises the "gut-brain axis." This axis is vital for maintaining body homeostasis. This axis is altered in many metabolic and mental dysfunctions/disorders. [4] The normal microbial flora is also responsible for the "colonization resistance" phenomenon, i.e., the normal commensal bacteria can prevent colonization of disease-causing pathogens. The normal microbial flora occupies the niche, causing limitation of the nutrients and available space, and thus prevents colonization by foreign pathogens. Again, many commensal colonizers produce inhibitory substance against pathogenic species. Many streptococcal commensals in the oral cavity synthesize inhibitory substance, to prevent colonization by other colonizers, e.g., production of hydrogen peroxide by Streptococcus sanguinis. Oral microbiome also has role in maintaining the level of nitrite and thus possess indirect role in maintaining cardiovascular health. [1] Data from human microbiome project have shown that alteration in the normal microbiota is associated with many diseases, including obesity, periodontitis, inflammatory bowel disease, irritable bowel syndrome, diabetes, cancer, rheumatoid arthritis, Alzheimer's disease, and Parkinsonism's disease. [2, 5] Alteration of this microbiota is associated with disease state; the biggest example is antibiotic-associated diarrhea. The organism responsible is Clostridium difficile, and broad-spectrum penicillins, clindamycin, and cephalosporins are the most common culprits. Almost 5%-10% of patients on ampicillin, 15%-20% of patients on cefixime, and 10%-25% of patients receiving amoxicillin-clavulanic acid complain of diarrhea at different stages of their treatment. Antibiotics reaching colon in higher amounts (e.g., poorly absorbed in the upper part of intestine) are the frequent culprit. However, antibiotics reaching intestine through bile duct are also equally responsible. Use of these agents disrupts the normal commensal flora and subsequent overgrowth of C. difficile and development of symptoms, e.g., diarrhea, fever, and colitis. [6] Here comes the importance of development of highly selective antimicrobials, which kills the targeted organism selectively and at the same time does not alter the prevalent microbial flora.
Specifically Targeted Antimicrobial Peptides
STAMPs stand for "specifically targeted antimicrobial peptides," which are designed to selectively target and kill specific pathogens and at the same time without affecting the normal microbial flora. Eckert et al. (2006) were a pioneer in this field to propose the ideas of developing STAMPs to combat antimicrobial resistance with minimal or no impact on the normal commensals. [7] STAMPs typically consist of two regions, targeting and killing regions, which are independent functionally and joined by a linker. The targeting region enhances the activity of the peptide molecule by enhancing binding to the target pathogen with the help of specific determinants and thus leads to accumulation of the killing moiety in the selective pathogens. [8] Specifically Targeted Antimicrobial Peptide against Streptococcus mutans Huo et al. have developed and evaluated 11 STAMPs and also evaluated its effect on the growth of Streptococcus Editorial mutans biofilm, among which five STAMPs, i.e., C8H, C11H, C12H, C13H, and C14H, significantly inhibited the growth of biofilm of S. mutans, without significant effect on biofilm of Streptococcus gordonii and S. sanguinis biofilm. Among the STAMPs evaluated, highest efficacy was shown by C11H and C12H. The STAMPs showed antibacterial activity against S. mutans grown in planktonic or biofilm states, without significant alteration of oral streptococci and multi-species biofilm. [9] Another significant advancement in the selective targeting of S. mutans is the development of C16G2, the targeting region of which is S. mutans competence stimulation peptide and the killing component is G2, which is a broad-spectrum antimicrobial peptide. High selectivity of C16G2 toward S. mutans was demonstrated in vitro in both mono-species and multi-species cultures (saliva-derived) spiked with S. mutans. After 24 h, it was seen that bacterial species with a symbiotic relation with S. mutans also reduced significantly, and on the contrary, health-associated streptococci became the dominant species. [10] This implies the therapeutic potential of the compound.
Multiple-Headed Specifically Targeted Antimicrobial Peptide: Targeting Pseudomonas aeruginosa and Streptococcus mutants Together
The conventional STAMPs usually contain one targeting region and one killing agent. As an extension of this concept, He et al. developed a STAMP with multiple-targeting regions, targeting two different bacteria. They have developed a multiple-headed STAMP named as M8(KH)-20, in which multiple-targeting heads were attached to an AMP using a lysine residue branch point. This peptide demonstrated specific activity against Pseudomonas aeruginosa and Streptococcus mutants in vitro, with little effect on other species. [11] Another antimicrobial peptide "novispirin G10" is converted to a STAMP named as "G10KHc." G10KHc had enhanced ability to kill P. aeruginosa in the clinical isolates. Efficacy of G10KHc was similar and synergistic action was noted when G10KHc was combined with neosporin. [7] 
Specifically Targeted Antimicrobial Peptide Targeting Methicillin-Resistant

Staphylococcus aureus
Agplectasin is a STAMP created by fusing AgrD1 pheromone to the N-terminal end of plectasin. It is especially effective against methicillin-resistant S. aureus. Mao et al. developed recombinant Agplectasin. This recombinant form also showed strong cidal action toward S. aureus, but other components of normal flora, e.g., Staphylococcus epidermidis, remained unaffected, which highlighted its high specificity. [12] 
Current Status in Clinical Phase
Although many of the STAMPs showed promising activity in vitro and in preclinical studies, till now, only very few have reached the clinical evaluation stage. Sullivan et al. evaluated the efficacy of C16G2 mouth rinse (0.04% w/v) for targeted elimination of S. mutans and prevention of demineralization in both in vitro and in clinical settings (in an intraoral remineralization/demineralization model). Single treatment with C16G2 led to selective elimination of S. mutans both from saliva and plaque, which resulted in a healthy plaque, without disturbing the remaining microbial flora. This healthy flora even resisted S. mutans growth in spite of repeated sucrose challenges. This resulted in a healthy plaque, which showed a significant resistance toward enamel demineralization. [13] Currently, C16G2 has completed phase 2 clinical trials. [14] 
Conclusion and Future Perspective
Alteration of the normal microbiome results in dysbiosis and subsequent disease conditions or altered pathophysiology. Development of STAMPs is a very significant advancement in this regard. Although lots of STAMPs showed promising effects, very few have reached the clinical evaluation stages. We need more focused research (both preclinical and clinical) in these areas for better development of microbiome-friendly antimicrobials with clinical utility.
